No Picture
News

Phoenix Molecular Designs Initiates its Phase 1/1b Program to Evaluate PMD-026 in Patients with Resistant Forms of Advanced Breast Cancer

SAN DIEGO and VANCOUVER, British Columbia, Nov. 20, 2019 /PRNewswire/ — Phoenix Molecular Designs (PhoenixMD), a clinical stage biotechnology company developing precise cancer therapeutics targeting essential kinases, announced today that it has d… […]

No Picture
News

Viking Therapeutics Announces Initiation of Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)

Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Range of VK2809 Doses for up to 52 Weeks

SAN DIEGO, Nov. 19, 2019 /PRNewswire/ — Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical compan… […]

No Picture
News

Neurocrine Biosciences Publishes Long-Term INGREZZA® (valbenazine) Data in the Journal of Clinical Psychopharmacology Demonstrating Once-Daily 40 mg and 80 mg Capsules Reduced Involuntary Movements in Adults with Tardive Dyskinesia

– Approximately 90% of Patients Treated with INGREZZA in the Open-Label KINECT 4 Phase III Study Achieved a 50% or Greater Improvement in Their Tardive Dyskinesia Symptoms- INGREZZA Continues to Be Well Tolerated Through One Year of Treatment

SAN D… […]

No Picture
News

DURECT Corporation Announces Positive Results from the Phase 2a Clinical Trial of DUR-928 in Alcoholic Hepatitis Patients in a Late-Breaking Presentation at The Liver Meeting®

Live Webcast of Data Presentation and Discussion by KOL, Tarek I. Hassanein, M.D. at Noon ET on Tuesday, November 12, 2019

CUPERTINO, Calif., Nov. 12, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced the results from its Phase 2… […]

No Picture
News

Tocagen Highlights Toca 6 Phase 1b Data at Society for Immunotherapy of Cancer Annual Meeting

Phase 3 Toca 5 trial data and details on planned trial in newly diagnosed glioblastoma to be presented at Society for Neuro-Oncology Annual Meeting

SAN DIEGO, Nov. 8, 2019 /PRNewswire/ — Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selectiv… […]

No Picture
News

CalciMedica to Present Results of PD/PK Study in Acute Pancreatitis Patients for its CRAC Channel Inhibitor CM4620 at APA Annual Meeting

LA JOLLA, Calif., Nov. 7, 2019 /PRNewswire/ — Kenneth Stauderman, Ph.D., CalciMedica’s Chief Scientific Officer, is presenting a poster at the American Pancreas Association annual meeting November 7-10 in Wailea, Hawaii, entitled “Pharmacodynamic … […]

No Picture
News

DURECT to Host Key Opinion Leader Call on DUR-928 Phase 2a Alcoholic Hepatitis Study Results

Call will feature data from DURECT’s late-breaking oral presentation at the 2019 Liver Meeting®

CUPERTINO, Calif., Nov. 6, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will host a key opinion leader (KOL) conference … […]

No Picture
News

Evofem Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update

Company on Track for Amphora NDA Resubmission to the U.S. FDAPhase 2b AMPREVENCE Trial Results Anticipated in Q4 2019Management to Host Conference Call Thursday, November 7, 2019 at 11:00 a.m. EST

SAN DIEGO, Nov. 6, 2019 /PRNewswire/ — Evofem Biosci… […]